Physician profile
Gigy Sam
NPI 1992149991
$741.79
in general payments reported to CMS, 2019-2025
20 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.13 · 2023: $229 · 2024: $214 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $138.26 | 2023-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.70 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $61.92 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Glaxosmithkline, LLC. | $59.73 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $57.63 | 2023-2025 | Otezla, Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $39.45 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $35.10 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $34.07 | 2023-2024 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $27.39 | 2022-2024 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $24.96 | 2022 | |
| Dexcom, INC. | $21.76 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $20.39 | 2025 | Korlym |
| Azurity Pharmaceuticals, INC. | $19.93 | 2024 | Edarbyclor |
| Neurocrine Biosciences, INC. | $19.34 | 2024 | Ingrezza |
| Phadia US INC. | $18.88 | 2023 | Immunocap |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.91 | 2023 | Belsomra, Steglatro |
| Novo Nordisk INC | $16.73 | 2025 | Ozempic, Rybelsus |
| Shield Therapeutics INC | $16.06 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.44 | 2023 | Xifaxan, Trulance |
| Pfizer INC. | $14.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gigy Sam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.